ArchiveMay 2019

Getting rid of MRI as an outcome measure in trials may be feasible

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS Maria Pia Sormani, Dieter A. Haering, Harald Kropshofer, David Leppert, Uma Kundu, Christian Barro, Ludwig Kappos, Davorka Tomic, Jens Kuhle Objectives To assess whether neurofilament light chain (NfL) could serve as an informative endpoint in Phase 2 studies in patients with relapsing–remitting multiple sclerosis (RRMS)...

Going round the guts to get to the brain.

MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis. Kuhbandner K, Hammer A, Haase S, Terbrack E, Hoffmann A, Schippers A, Wagner N, Hussain RZ, Miller-Little WA, Koh AY, Stoolman JS, Segal BM, Linker RA, Stüve O. Front Immunol. 2019;10:903 Lymphocyte homing into the intestine is mediated by binding of leukocytes to...

Autoimmunity and Alemtuzumab (CAM-Thy)

Secondary Autoimmunity after alemtuzumab, is one of the problems associated with this drug. It was suggested that autoimmunity occurred in people who repopulated their T cells from memory cells compared to getting new ones from the thymus. So the suggestion was that if you make more cells from the thymus you get a more diverse T cell repertoire you get less autoimmunity. The Cambridge group...

HSV-2 encephalitis with Ocrelizumab

The effect of DMTs on lymphocytes causing lymphopenia (from E Fox et al. Neuol Clin Pract Feb 2019) Why does this not come as a surprise to all and sundry, the report of a potentially harmful infection following immunosuppressive treatment, but this time from the new kid on the block, ocrelizumab (Ocrevus). Not to sound cliched, but if you hadn’t seen this one coming, well then the rest is...

Generalised EBV vaccine a step closer?

EPO2229 – Preliminary phase 1 safety of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus (EBV)-targeted T-cell immunotherapy for patients with progressive multiple sclerosis (MS) Background and aims Epidemiological and serological evidence suggest EBV infection is associated with MS pathogenesis. Previously, we showed that treatment with an...

Cladribine, is cladribine, is cladribine

News from the European Academy of Neurology 2019. Our data is reproducible and oral cladribine does what we said it does. EPO1241 Changes in Lymphocyte subpopulations in Highly Active Multiple Sclerosis patients during Cladribine treatment.M. Ruggieri, C. Gargano, A. Iaffaldano, A. Manni, P. Iaffaldano, D. Paolicelli, M. Trojano; Bari/IT Background and aims: Background: Cladribine tablets 3...

Want some sleep? Take cannabis or maybe read a review about cannabis

The use of cannabinoids for sleep: A critical review on clinical trials.Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. Exp Clin Psychopharmacol. 2019 May 23. doi: 10.1037/pha0000285. [Epub ahead of print] Cannabis and its pharmacologically active constituents, phytocannabinoids, have long been reported to have multiple medicinal benefits. One association often reported by...

MS, it’s in the Genes

A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. International Multiple Sclerosis Genetics Consortium. Nat Commun. 2019:10(1):2236. Madireddy L, Patsopoulos NA, Cotsapas C, Bos SD, Beecham A, McCauley J, Kim K, Jia X, Santaniello A, Caillier SJ, Andlauer TFM, Barcellos LF, Berge T, Bernardinelli L, Martinelli-Boneschi...

To deplete or Not to Deplete.That is the Question? Microglia are the good Guys?

Microglia suppress the secondary progression of autoimmune encephalomyelitis.Tanabe S, Saitoh S, Miyajima H, Itokazu T, Yamashita T. Glia. 2019 May 20. doi: 10.1002/glia.23640. [Epub] So all you will remember here is microglia inhibit secondary progression. They are the good guys. Which is funny because we have been saying they are the bad guys. They report Microglia depletion...

AAN 2019 posters #3

All good things unfortunately come to an end, and sadly this is the last in the series of three on AAN 2019 posters. What has captured my attention from this years AAN has been the varied interests of the clinician scientists who have presented their work here. This is a good sign, because without varied interests, science and ultimately progress slowly comes to a standstill. I call it the...

Translate

Categories

Recent Posts

Recent Comments

Archives